Designated Organic Active Ingredient Containing (doai) Patents (Class 514/1)
  • Patent number: 10251887
    Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 9, 2019
    Assignee: University of Massachusetts
    Inventor: Louis M. Messina
  • Patent number: 10208167
    Abstract: A compound comprising a cyclodextrin and a monoalkoxy polyethylene glycol linked thereto through an ether bond (a “pegylated cyclodextrin”) is disclosed, as are drug delivery vehicles and pharmaceutical formulations including the same, and methods for making the compound and the drug delivery vehicle and for delivering the drug to a patient in need thereof. The method of making includes the steps of creating either a tosylated monoalkoxy polyethylene glycol or a tosylated cyclodextrin, and either reacting the tosylated monoalkoxy polyethylene glycol with a deprotonated cyclodextrin, or reacting the tosylated cyclodextrin with a deprotonated monoalkoxy polyethylene glycol. The present pegylated cyclodextrin readily forms an inclusion compound with certain drugs to protect the drug against adverse interactions with mucin (e.g., in a mucus membrane).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: February 19, 2019
    Assignee: The Board of Trustees of the California State University
    Inventors: Yong Ba, Kim Trang Huu Nguyen
  • Patent number: 10202428
    Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
  • Patent number: 10196345
    Abstract: Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: February 5, 2019
    Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, CENTRE FOR DRUG RESEARCH AND DEVELOPMENT
    Inventors: Edward Ewald Putnins, David Scott Grierson, Ronan F.B. Gealageas, Alice Andree Valentine Devineau, Edith Mary Dullaghan
  • Patent number: 10093961
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: October 9, 2018
    Assignee: ESPERANCE PHARMACEUTICALS
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 10053422
    Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Pitney Pharmaceuticals Pty Limited
    Inventors: Mohammad Hossein Pourgholami, David L. Morris, Roger Aston
  • Patent number: 10047137
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: August 14, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • Patent number: 9945853
    Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 17, 2018
    Assignees: Université Laval, Hérma-Québec, University of Washington
    Inventors: Eric Boilard, Luc Boudreau, Louis Thibault, Michael Herman Gelb
  • Patent number: 9918980
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: March 20, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 9913864
    Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 13, 2018
    Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE
    Inventor: Jeffrey Spees
  • Patent number: 9885083
    Abstract: Accordingly, in some embodiments methods for detecting an analyte or analytes in one or more sample(s) are provided. The methods encompass providing a solid support with an addressable marker and an associated ligand, contacting the solid substrate to a sample, thereby forming a contacted solid support, associating the contacted solid support with a FET array and detecting the electrical properties of the FET array and thereby detecting an analyte or analytes in one or more samples. In other embodiments, the sample encompasses a second addressable marker.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: February 6, 2018
    Assignee: Life Technologies Corporation
    Inventors: Scott Conradson, David Dinauer, Bin Zhao, Dmitriy Gremyachinskiy, Jason Myers, Jeffrey Rossio, Victoria Singer, Kristina Giorda
  • Patent number: 9861736
    Abstract: Methods are provided for collecting platelet-rich plasma. A disposable flow circuit is mounted to a fluid processing device having a fluid separation chamber and an injection device. A fluid containing plasma and platelets is continuously conveyed from a fluid source into the fluid separation chamber and processed to produce platelet-rich plasma. At least a portion of the platelet-rich plasma is automatically conveyed from the fluid separation chamber into the injection device, which is directly connected to a pump device such that at least a portion of the platelet-rich plasma from the fluid separation chamber is automatically conveyed into the pump device prior to being conveyed into the injection device. The injection device with the platelet-rich plasma is then detached from the disposable flow circuit.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: January 9, 2018
    Assignee: Fenwal, Inc.
    Inventors: John W. Barry, Jr., Brian C. Case, Jonathan Prendergast, Lan T. Nguyen, John Foley
  • Patent number: 9861652
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 9, 2018
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Patent number: 9758786
    Abstract: Provided herein are composition for sensitizing tumors to anti-tumor therapies. The compositions include antisense oligonucleotides against TGF?2, wherein the compositions sensitize tumors to anti-tumor therapies. Also provided herein are method for treating cancer using the compositions described herein.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: September 12, 2017
    Assignee: AUTOTELIC, LLC
    Inventor: Vuong Trieu
  • Patent number: 9695462
    Abstract: The present invention is related to a method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity wherein phosphatidylinositol or lysophosphatidylinositol is used as an indicator. The present invention is also related to a method for screening an inhibitor of EL activity using phosphatidylinositol and a kit for use in the method.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 4, 2017
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takashi Ono, Atsuko Yamamoto, Shuhei Shigaki
  • Patent number: 9689029
    Abstract: The invention provides systems and methods for processing samples. In a method, a reaction card is provided that has a channel network, a valve, and a micropump, all disposed within the card. The reaction card also has a collection well disposed on a surface of the card and a tubular member extending out from the card. A reaction vessel is provided and affixed to the reaction card such that the tubular member is inserted into the reaction vessel. Amplification reaction reagents and a sample are delivered into the reaction vessel, and an amplification reaction is initiated within the reaction vessel, resulting in an amplification product being disposed within the reaction vessel. The valve is opened to atmosphere, and the first micropump is activated to pump an aliquot of reaction product from the reaction vessel into the tubular member, through the channel network, and into the collection well.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: June 27, 2017
    Assignee: Caliper Life Sciences, Inc.
    Inventors: Edward H. Thorne, IV, Abbie L. Esterman
  • Patent number: 9670288
    Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: June 6, 2017
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
  • Patent number: 9656986
    Abstract: In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 23, 2017
    Assignee: MYCELL TECHNOLOGIES, LLC
    Inventor: Volker Berl
  • Patent number: 9651562
    Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 16, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hon Wai Koon, Charalabos Pothoulakis
  • Patent number: 9622947
    Abstract: The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: April 18, 2017
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Patent number: 9579321
    Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 28, 2017
    Assignee: University of Massachusetts
    Inventor: Louis M. Messina
  • Patent number: 9545390
    Abstract: An antiseptic composition suitable for use on skin and wounds comprising a source of an antimicrobial agent and an agent which disrupts biofilms. More, particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: January 17, 2017
    Assignee: Convatec Technologies Inc.
    Inventors: Steven L. Percival, Phillip G. Bowler, David Parsons
  • Patent number: 9460246
    Abstract: Non-mechanistic, differential-equation-free approaches for predicting a particular non-linear, response of a system to a given input are provided in the form of systems, methods, and devices. These approaches are generally directed to a non-compartmental method of predicting a non-linear, time-dependent response of a component of a system to an input into the system. The systems, methods, and devices provide the ability to (i) reduce the cost of research and development by offering an accurate modeling of heterogeneous and complex physical systems; (ii) reduce the cost of creating such systems and methods by simplifying the modeling process; (iii) accurately capture and model inherent nonlinearities in cases where sufficient knowledge does not exist to a priori build a model and its parameters; and, (iv) provide one-to-one relationships between model parameters and model outputs, addressing the problem of the ambiguities inherent in the current, state-of-the-art systems and methods.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: October 4, 2016
    Assignee: ARRAPOI, INC.
    Inventor: Glenn A. Williams
  • Patent number: 9452148
    Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: September 27, 2016
    Assignee: Verva Pharmaceuticals Ltd
    Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
  • Patent number: 9453198
    Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: September 27, 2016
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stuart M. Chambers, Yuchen Qi, Yvonne Marissa Mica
  • Patent number: 9441199
    Abstract: Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: September 13, 2016
    Assignee: SanBio, Inc.
    Inventor: Mari Dezawa
  • Patent number: 9439979
    Abstract: Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: September 13, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John Chiorini, Melodie L. Weller, Michael Schmidt
  • Patent number: 9377461
    Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of any of SEQ ID NOs: 1 to 3, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: June 28, 2016
    Assignee: FUJIFILM Corporation
    Inventors: Sumio Sugano, Yukari Kanzaki, Tsuneo Saga, Atsushi Tsuji
  • Patent number: 9289423
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 22, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Mary Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 9283185
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 15, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
  • Patent number: 9278088
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Patent number: 9259426
    Abstract: This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene; R6 is halogen, heteroaryl or aryl; R? and R? are each independently hydrogen, C1-7 alkyl-carbonyl or C1-7 alkyl; provided that R4 is not phenyl substituted with morpholino when R2 is H and R5 is H, and provided that when NR4R5 is piperazinyl, said NR4R5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: February 16, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Ling-Jie Gao, Piet André Maurits Maria Herdewijn, Steven Cesar Alfons De Jonghe, William John Watkins, Lee Shun Chong
  • Patent number: 9259409
    Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: February 16, 2016
    Assignee: Inceptum Research & Therapeutics, Inc.
    Inventor: Fabrizio G. Mastronardi
  • Patent number: 9243301
    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 26, 2016
    Assignees: Allergan, Inc., Ipsen Bioinnovation Limited
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
  • Patent number: 9186370
    Abstract: Some embodiments of the present invention relate to methods and compositions for treating cancer. More embodiments include methods and compositions for modulating the activity of the Hedgehog pathway.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: November 17, 2015
    Assignee: University of South Alabama
    Inventors: Lalita Samant, Rajeev Samant, Shamik Das, Eddie Reed
  • Patent number: 9180138
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: November 10, 2015
    Assignees: University of Georgia Research Foundation, Inc., Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Patent number: 9157906
    Abstract: The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: October 13, 2015
    Assignees: THE ROCKEFELLER UNIVERSITY, THE CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Paul Greengard, David Repaske, Gretchen Snyder
  • Patent number: 9115183
    Abstract: Recombinant proteins capable of inducing platelet aggregation and uses thereof.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: August 25, 2015
    Assignee: CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON
    Inventors: David Vandroux, Emmanuel De Maistre, Edouard Prost
  • Patent number: 9114159
    Abstract: The present invention relates to methods of altering the competence of a dendrite and/or the viability of a neuron by modulating the level of Elk-1 in a dendrite. The present invention also provides methods of altering the ATP levels in a neuron, methods of isolating at least one protein of a mitochondrial permeability transition pore complex, methods of introducing an RNA into a neuron, methods of translating an RNA in a dendrite, methods of monitoring risk of neurodegeneration of a neuron, and methods of treatment for neurodegenerative diseases.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: August 25, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James H. Eberwine, Lindy E. Barrett
  • Patent number: 9101583
    Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: James Chang, Patrick Hughes, Chin-Ming Chang
  • Patent number: 9068166
    Abstract: Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: June 30, 2015
    Assignee: Industry-Academic Cooperation Foundation Yonsei University
    Inventors: Ki Chul Hwang, Yang Soo Jang, Gyoon Hee Han
  • Patent number: 9045470
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: June 2, 2015
    Assignee: IRM LLC
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Kathy Yue, Xiaoyue Zhang, Manmohan Singh, David Skibinski
  • Patent number: 9044503
    Abstract: Methods for treatment and/or prevention of Alzheimer's disease comprising inactivating peripheral AP in serum to a reduce A(3 in the brain. Methods comprise expression of amyloid peptide inactivating enzyme on bone marrow cells; and coupling of amyloid peptide inactivating enzyme to hematopoietic cells.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 2, 2015
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Louis B. Hersh, Hanjun Guan
  • Patent number: 9029315
    Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The University of Hong Kong
    Inventors: Zhiwei Chen, Jingying Zhou
  • Patent number: 9029342
    Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: May 12, 2015
    Assignees: Board of Regents of the University of Texas System, OTC Technologies, LLC
    Inventors: Kenneth Michael Hargreaves, John Gordon Bruno
  • Patent number: 9018190
    Abstract: The invention relates to an oligodextran, chosen from dextrans whose average degree of polymerization is less than 10, modified by at least one substituent of general formula I: —R1-[[AA]-[R2]n]m??formula I It also relates to a pharmaceutical composition characterized in that it comprises an oligosaccharide according to the invention and an active ingredient is chosen from the group consisting of proteins, glycoproteins, peptides and non-peptide therapeutic molecules.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: April 28, 2015
    Assignee: ADOCIA
    Inventors: Richard Charvet, Remi Soula, Olivier Soula
  • Patent number: 9018155
    Abstract: The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed to Staphylococci.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: April 28, 2015
    Assignee: Hyglos Invest GmbH
    Inventors: Michael Forchheim, Holger Grallert, Anja Philipp, Manfred Biebl
  • Patent number: 8993639
    Abstract: The invention relates to the use of a L-theanine for the treatment of gastroesophageal reflux disease (e.g., heartburn) in a human or animal, including useful methods and compositions.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: March 31, 2015
    Inventors: Burt Shulman, Barrie R. Froseth, Ravindranath S. Menon
  • Patent number: 8993509
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I).
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: March 31, 2015
    Inventors: Robert Zimmerman, Rudolf Zechner, Günther Haemmerle, Gerald Höfler, Suman Das, Achim Lass
  • Patent number: 8987189
    Abstract: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HCV release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: March 24, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jin Ye, Fang Sun, Hua Huang, Michael J. Gale